Neon Therapeutics

About:

NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.

Website: https://neontherapeutics.com/

Twitter/X: neon_tx

Top Investors: Fidelity, Hillhouse Investment, Wellington Management, Third Rock Ventures, Access Industries

Description:

Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.

Total Funding Amount:

$161M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)neontherapeutics.com

Founders:

Catherine Wu, Ed Fritsch, Eric Lander, James P. Allison, Nir Hacohen, Robert D. Schreiber, Ton Schumacher

Number of Employees:

51-100

Last Funding Date:

2017-12-05

IPO Status:

Public

Industries: